List of Excipients in API SARECYCLINE HYDROCHLORIDE
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing SARECYCLINE HYDROCHLORIDE
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Almirall LLC | SEYSARA | sarecycline hydrochloride | 16110-245 | CELLULOSE, MICROCRYSTALLINE | 2033-02-09 |
| Almirall LLC | SEYSARA | sarecycline hydrochloride | 16110-245 | D&C YELLOW NO. 10 | 2033-02-09 |
| Almirall LLC | SEYSARA | sarecycline hydrochloride | 16110-245 | FERRIC OXIDE YELLOW | 2033-02-09 |
| Almirall LLC | SEYSARA | sarecycline hydrochloride | 16110-245 | METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER | 2033-02-09 |
| Almirall LLC | SEYSARA | sarecycline hydrochloride | 16110-245 | POLYETHYLENE GLYCOL | 2033-02-09 |
| Almirall LLC | SEYSARA | sarecycline hydrochloride | 16110-245 | POLYVINYL ALCOHOL | 2033-02-09 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for SARECYCLINE HYDROCHLORIDE
Excipient focus: CELLULOSE, MICROCRYSTALLINE
SARECYCLINE HYDROCHLORIDE drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Almirall LLC | sarecycline hydrochloride | 16110-245 |
| >Company | >Ingredient | >NDC |
SARECYCLINE HYDROCHLORIDE drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: D&C YELLOW NO. 10
SARECYCLINE HYDROCHLORIDE drug variants containing D&C YELLOW NO. 10
| Company | Ingredient | NDC |
|---|---|---|
| Almirall LLC | sarecycline hydrochloride | 16110-245 |
| >Company | >Ingredient | >NDC |
SARECYCLINE HYDROCHLORIDE drug variants not containing D&C YELLOW NO. 10
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
SARECYCLINE HYDROCHLORIDE drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Almirall LLC | sarecycline hydrochloride | 16110-245 |
| >Company | >Ingredient | >NDC |
SARECYCLINE HYDROCHLORIDE drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER
SARECYCLINE HYDROCHLORIDE drug variants containing METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER
| Company | Ingredient | NDC |
|---|---|---|
| Almirall LLC | sarecycline hydrochloride | 16110-245 |
| >Company | >Ingredient | >NDC |
SARECYCLINE HYDROCHLORIDE drug variants not containing METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
SARECYCLINE HYDROCHLORIDE drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Almirall LLC | sarecycline hydrochloride | 16110-245 |
| >Company | >Ingredient | >NDC |
SARECYCLINE HYDROCHLORIDE drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
SARECYCLINE HYDROCHLORIDE drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Almirall LLC | sarecycline hydrochloride | 16110-245 |
| >Company | >Ingredient | >NDC |
SARECYCLINE HYDROCHLORIDE drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE
SARECYCLINE HYDROCHLORIDE drug variants containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Almirall LLC | sarecycline hydrochloride | 16110-245 |
| >Company | >Ingredient | >NDC |
SARECYCLINE HYDROCHLORIDE drug variants not containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM BICARBONATE
SARECYCLINE HYDROCHLORIDE drug variants containing SODIUM BICARBONATE
| Company | Ingredient | NDC |
|---|---|---|
| Almirall LLC | sarecycline hydrochloride | 16110-245 |
| >Company | >Ingredient | >NDC |
SARECYCLINE HYDROCHLORIDE drug variants not containing SODIUM BICARBONATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A POTATO
SARECYCLINE HYDROCHLORIDE drug variants containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| Almirall LLC | sarecycline hydrochloride | 16110-245 |
| >Company | >Ingredient | >NDC |
SARECYCLINE HYDROCHLORIDE drug variants not containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STEARYL FUMARATE
SARECYCLINE HYDROCHLORIDE drug variants containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| Almirall LLC | sarecycline hydrochloride | 16110-245 |
| >Company | >Ingredient | >NDC |
SARECYCLINE HYDROCHLORIDE drug variants not containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
SARECYCLINE HYDROCHLORIDE drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Almirall LLC | sarecycline hydrochloride | 16110-245 |
| >Company | >Ingredient | >NDC |
SARECYCLINE HYDROCHLORIDE drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
SARECYCLINE HYDROCHLORIDE drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Almirall LLC | sarecycline hydrochloride | 16110-245 |
| >Company | >Ingredient | >NDC |
SARECYCLINE HYDROCHLORIDE drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch